Ion channel proteins are required for both the establishment of resting membrane potentials and the generation of action potentials. Hundreds of mutations in genes encoding voltage-gated ion channels responsible for action potential generation have been found to cause severe neurological diseases. In contrast, the roles of voltage-independent ''leak'' channels, important for the establishment and maintenance of resting membrane potentials upon which action potentials are generated, are not well established in human disease. UNC80 is a large component of the NALCN sodium-leak channel complex that regulates the basal excitability of the nervous system. Loss-of-function mutations of NALCN cause infantile hypotonia with psychomotor retardation and characteristic facies (IHPRF). We report four individuals from three unrelated families who have homozygous missense or compound heterozygous truncating mutations in UNC80 and persistent hypotonia, encephalopathy, growth failure, and severe intellectual disability. Compared to control cells, HEK293T cells transfected with an expression plasmid containing the c.5098C>T (p.Pro1700Ser) UNC80 mutation found in one individual showed markedly decreased NALCN channel currents. Our findings demonstrate the fundamental significance of UNC80 and basal ionic conductance to human health.
Among mammalian neurons from different brain regions, there is considerable variability in basal excitability and resting membrane potentials (from approximately À85 mV to À50 mV) upon which action potentials are generated. Many mutations in voltage-gated ion channels responsible for the generation of action potentials have been found to cause severe diseases, including migraine, episodic muscle paralysis, ataxia, epilepsy, autism, and sudden cardiac death (see Jurkat-Rott et al., Kullmann and Waxman, and Catterall et al. [1] [2] [3] for reviews). In contrast, the molecular mechanisms and the role of basal excitability in human diseases are not well understood. The resting membrane potential is primarily determined by ion channels that are open and ''leaky'' at rest. The basal Na þ leak is mainly established through the NALCN Na þ -leak channel. In mouse hippocampal neurons, NALCN is responsible for~70% of the total basal Na þ leak. 4 NALCN is a member of the 24-transmembrane domain (24-TM) ion channel superfamily, which includes the ten voltage-gated Ca 2þ channels and ten Na þ channels. 5 It forms a voltage-independent, Na þ -permeable, non-selective, non-inactivating cation channel. NALCN's unique properties allow it to generate background sodium-leak currents. The balance between Na þ influx through NALCN and K þ efflux through other channels is predicted to generate a large dynamic range of neuronal excitability. In mammalian brains, the NALCN complex also contains UNC79 and UNC80, homologs of C. elegans Unc-79 and Unc-80. [6] [7] [8] In situ hybridization analysis, RNA sequencing (RNA-seq), and expression sequence-tag (EST) database searches suggest that NALCN (MIM: 611549), UNC79, and UNC80 (MIM: 612636) are widely expressed in the brain. 4 Both UNC79 and UNC80 are large proteins (~3,000 amino acids) but do not have recognizable domains. NALCN and UNC79 do not directly interact with each other; the three components are brought together by UNC80's association with both UNC79 and NALCN. 6, 7 UNC80 is required for the channel's regulation 
by extracellular Ca 2þ through a G-protein-dependent pathway and by neuropeptides, such as substance P, through a G-protein-independent pathway that also requires the Src family of kinases.
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In worms and flies, mutations in Nalcn, Unc-79, and Unc-80 lead to uncoordinated movements, abnormal circadian rhythms, and altered sensitivity to anesthetics. [9] [10] [11] [12] [13] In mice, knocking out Nalcn or Unc79 leads to severe apnea and neonatal lethality. 4, 5, 7 In humans, inherited homozygous loss-of-function NALCN mutations cause infantile hypotonia with psychomotor retardation and characteristic facies (IHPRF [MIM: 615419]). 14, 15 De novo heterozygous NALCN mutations are also found in individuals with arthrogryposis, hypotonia, intellectual disability, and developmental delay. 16, 17 Despite its widespread expression in the brain, the in vivo function of UNC80 is largely unknown, and no mutations in mammals have been reported. We report the identification and characterization of UNC80 mutations as the cause of severe neurological phenotypes in four female individuals from three unrelated families.
The four subjects have similar phenotypes characterized by severe hypotonia of neonatal onset and that persists until adolescence, motor delays, lack of independent ambulation, constipation, encephalopathy, seizures, absent speech, and severe intellectual disability. The clinical features and genetic results of all subjects are summarized in Table 1 and Figure 1 . Research protocols were approved in each country via institutional research boards and regional ethics committees, in keeping with national guidelines and the principles laid out in the Declaration of Helsinki. For the Norwegian family (F3), molecular analyses were performed in accordance with the Norwegian National Biotechnology Act. All parents provided written informed consent for study participation for themselves and their children, as well as for publication of clinical information, molecular findings, and photographs.
For family 1, the whole-exome sequencing (WES) library preparation, exon capture, and sequencing were performed at the Genome Québec Innovation Center (Montréal) as previously described. 18 Genomic DNA was captured with the SureSelect Human 50 Mb All Exon V5 kit (Agilent Technologies). Sequencing was performed on an Illumina HiSeq 2000 (Illumina) with paired-end 100-bp reads. A mean coverage of 1343 was obtained, and 97% of the bases were covered at more than 103. WES trio average coverage was 553. Read alignment, variant calling, and annotation were done with a pipeline based on the Burrows-Wheeler Aligner (BWA), SAMtools, ANNOVAR, and custom annotation scripts, and reads were aligned to the reference human genome (UCSC Genome Browser hg19). For family 2, DNA capture was performed with the SeqCap EZ Exome v.3.0 (Roche Nimblegen). Sequencing was performed on an Illumina HiSeq 2000 (Illumina) with paired-end 100-bp reads. A mean coverage of 763 was obtained, and 94% of the bases were covered at more than 103. Read alignment to the reference human genome (hg19) and variant calling were done with a pipeline based on BWA-MEM v.0.7 and the Genome Analysis Toolkit (GATK v.3.1-1-g07a4bf8). Variant annotation and prioritizing were done with Cartagenia NGS Bench (Cartagenia). Measurements for individual II.3 were taken at the last examination at the age of 9 years, rather than at the current age. b Based on UCSC Genome Browser GRCh37.
Four individuals from family 3 were tested and included in the Center for Mendelian Genomics project at the Baylor College of Medicine (BCM) in Houston, Texas. The WES method used at the BCM-HGSC (Human Genome Sequencing Center) has previously been described. 19 In brief, DNA was prepared for Illumina paired-end libraries, and capture was performed with the in-house-developed BCM-HGSC Core design and sequenced on the Illumina HiSeq 2500 platform (Illumina). Subject F1-IV.1 was found to be homozygous for a c.5098C>T missense variant (p.Pro1700Ser) in exon 32 of UNC80 (GenBank: NM_032504.1). The variant is predicted to be deleterious and is present at a position completely conserved among all animals ( Figure S3 ). The subject's father was unable to be tested, but her mother was confirmed to be a carrier of the variant (Figure 2 ). Subject F2-V.5 had a homozygous missense variant in UNC80, c.7607G>C (p.Arg2536Thr). G7607 is the last nucleotide of exon 50. The c.7607G>C variant disrupts the ''AG'' exonic sequence commonly found in exonintron junctions upstream of the conserved splice-donor sequence ''GT.'' The variant is predicted by five independent methods to affect splicing efficiency ( Figure S4 ). Splicing studies of UNC80 were not performed because UNC80 is not expressed in peripheral leukocytes and no other tissue was available from this individual. The variant (p.Arg2536Thr) is also predicted to neutralize a charged residue highly conserved in all animals ( Figure S5 ), suggesting that the variant disrupts protein function even in transcripts that are correctly spliced. Splicing analysis in neurons and functional characterization of the corresponding protein are required to determine the molecular consequence of this variant. Both healthy parents of subject F2-V.5 were heterozygous carriers, and all four healthy siblings were either heterozygous or bi-allelic wild-type (WT) at this nucleotide position (Figure 2 ). Subject F3-II.1 and subject F3-II.3 were both found to be compound heterozygous for the following UNC80 variants: c.2033delA (p.Asn678Thrfs*15) and c.7757T>A (p.Leu2586*) (GenBank: NM_032504.1). Both parents were found to be heterozygous carriers of one of the variants (Figure 2) . None of the variants were present in publically available databases (dbSNP, 1000 Genomes, and the ExAC Browser), and the c.5098C>T variant was found in the heterozygous state in one individual in the database of over 3,000 exomes at the Center for Mendelian Genomics.
The three mutations in subjects F2-V.5, F3-II.1, and F3-II.3 are predicted to lead to disruption (in F2-V.5, due to aberrant splicing) or truncation (in F3-II.1 and F3-II.3) of UNC80 and are most likely loss-of-function mutations. To determine whether the c.5098C>T missense variant (p.Pro1700Ser) in subject F1-IV.1 affects expression and function of UNC80, we introduced the variant into mouse Unc80 cDNA, which encodes a protein with 97% identity to the human UNC80 and has been functionally characterized. The mouse Unc80 cDNA (GenBank: FJ210934) was cloned into the EcoRI and NotI sites of vector pcDNA3.1. The p.Pro1769Ser variant (equivalent to human p.Pro1700Ser) was introduced with the Gibson assembly method. The sequences of the primers used for mutagenesis are as follows:
The mutation was confirmed with Sanger sequencing. We transfected the WT and variant Unc80 into human HEK293T cells (from ATCC, maintained in DMEM [GIBCO] supplemented with 10% FBS [Atlanta Biologicals] and 13 Glutamax [GIBCO]; transfection done with Lipofectamine 2000 as the transfection reagent). The Unc80 variant yielded an amount of protein comparable to that yielded by the WT Unc80 ( Figure 3A , lower two panels), suggesting that this missense variant does not disrupt production of the protein. The variant protein also retained its ability to associate with UNC79 ( Figure 3A ) and NALCN ( Figure 3B ), which was tested by co-immunoprecipitation.
We next used electrophysiological assays to test whether the p.Pro1769Ser (mouse equivalent of p.Pro1700Ser) variant affects the function of UNC80. A unique property of UNC80 is its ability to scaffold Src kinase and to enhance NALCN currents through a Src-dependent pathway. 6, 8 We recorded NALCN currents from HEK293T cells that we cotransfected with NALCN cDNA (human isoform, 7 in a pTracer vector expressing GFP under a separate promoter) and WT or variant Unc80 by using patch clamp pipettes containing a peptide Src activator ( Figure 4A , lower panel). Compared to those in cells transfected with WT Unc80, the sizes of the currents were significantly reduced in cells expressing the variant ( Figures 4B and 4C ). In summary, our studies reveal a genetic cause for global developmental delay and neurological dysfunction and demonstrate the importance of UNC80 in humans. From a motor perspective, all four individuals were significantly delayed in sitting; one individual was still unable to achieve this at the age of 4 years. None of the individuals were able to ambulate independently. These symptoms are comparable with those observed in individuals with loss-of-function NALCN mutations. 14, 15 Unlike individuals with NALCN mutations, our four UNC80 individuals show no true facial dysmorphism, although their faces are characterized by features related to severe hypotonia. All individuals in our study were described as encephalopathic, both clinically and on electroencephalogram (EEG) monitoring. Growth failure, severe constipation, and the feeding difficulties requiring G-tube insertion might be due, in part, to dysfunctional muscle coordination via neuronal compromise; however, standardized evaluation of swallowing function for all individuals would be required to confirm this. Subject F1-IV.1 also had severe sleep disturbance, including complete reversal of her sleep-wake cycle, which was resistant to treatment with melatonin. Subject F2-V.5 also had sleep disturbance, including difficulty falling asleep. In flies and mice, NALCN is essential for the depolarization of clock neurons in the morning and the maintenance of normal circadian rhythms. 26 It is possible that abnormal UNC80 prevents activation of the NALCN complex and inhibits the ability of pacemaker neurons to maintain basal sleep-wake rhythm.
Compared to phenotypes associated with mutations found in known neuronal genes, the neurological phenotypes we describe in these four UNC80 individuals are at the severe end of the spectrum. This underscores the pivotal importance of leak ion channel genes and the associated basal excitability in human health and disease.
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We would like to thank the participants and families for their contribution to this study. This work was selected for study by the Care4Rare Canada (Enhanced Care for Rare Genetic Diseases in Canada) Consortium Gene Discovery Steering Committee: Kym Boycott (lead; University of Ottawa), Alex MacKenzie (colead; University of Ottawa), J.M. (McGill University), Michael Brudno (University of Toronto), Dennis Bulman (University of Ottawa), and David Dyment (University of Ottawa). We also thank Hanne S. Sorte and Mari Ann Kulseth (Department of Medical Genetics, Oslo University Hospital) for excellent technical assistance. J.R.L. has stock ownership in 23andMe, is a paid consultant for Regeneron Pharmaceuticals, has stock options in Lasergen, is a member of the Scientific Advisory Board of Baylor Miraca Genetics Laboratories, and is a co-inventor on multiple US and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, and bacterial genomic fingerprinting This is a four-year-old girl who is the only child of healthy Iraqi parents who are first cousins. Family history is otherwise non-contributory. She was born via spontaneous vaginal delivery at 41 weeks gestation after a normal pregnancy, with a birth weight of 3000 g and Apgar scores of 9 at one and five minutes. She was hypotonic, with feeding difficulties and severe constipation. At age 2 weeks, she was investigated for possible Hirschsprung's disease; however, a rectal biopsy was normal. At age three months she developed generalized tonic-clonic seizures. These were well-controlled with Clonazepam, and she has been seizure-free for the past year. A subglottic web was detected in conjunction with investigations for frequent recurrent febrile episodes between ages four and nine months. At age 2 years a G-tube was placed due to severe feeding difficulties, however she continues to fail to thrive. Currently at age four years, she is able to sit independently for a few seconds. She rolled from supine to prone at age three years, but is not able to crawl, stand or walk, and does not have a pincer grasp. She can bring her hands to the midline and transfer objects from hand to hand. She babbles but does not have any speech, and does not follow commands. She has little interest in her surroundings, and makes occasional eye-contact. She has severe sleep disturbance with reversed sleep-wake cycle, despite treatment with melatonin 4 mg qhs, and obstructive sleep apnea. She also has choreiform movements, hypothyroidism and superficial punctate keratopathy. An EEG was suggestive of encephalopathy at age 10 months. MRI of the brain revealed global reduction in cerebral volume, a thin corpus callosum, and myelination at the lower limit of normal. Mild non-specific myopathic changes were evident on muscle biopsy.
This is a 3.9-year-old girl born at 41 weeks after a normal pregnancy. The healthy parents, who are originally from Morocco, are first cousins once removed and she is their fifth child. Family history is otherwise non-contributory. Birth weight was 3158 g and Apgar scores were 8/10/10 after 1/5/10 minutes respectively. Hypotonia was noted from birth but was more prominent at age three months. At age 3.9 years she is a small child with generalized hypotonia. She has been able to sit without support since age 2.5 years but cannot stand. She makes sounds, but has no speech. She has myopathic facies, ptosis, and shallow nasolabial folds. ( Figure 1B ) Onset of epilepsy with tonic-clonic seizures was at age three years and 10 months. A G-tube was inserted at 3 years for feeding problems and recurrent upper airway infections thought to be related to malnourishment.
The following investigations were reported as normal: metabolic screening in urine and blood (age 10 months), chromosomal microarray (Agilent 180K Oligoarray), methylation analysis of the Silver-Russell syndrome critical regions on chromosomes 11 and 7, brain MRI (age 10 months), EEG (age 10 months), opthalmologic exam, visual evoked potentials (age two years and 11 months), brainstem auditory evoked potentials (age 2 years 11 months).
Subject F3-II.1 and Subject F3-II.3
These sisters were born to non-consanguineous healthy parents of Norwegian ethnicity at term with normal birth weights after uncomplicated pregnancies. At ages 15 and 9 years respectively, they remain extremely hypotonic and do not walk without support. Both are normocephalic with OFC in the low normal range. They babble socially, have very communicative body language but no meaningful speech. They are generally content children but sudden sounds, movements or changes in ambient light frighten them.
Tactile aversion, particularly on the soles of the feet, was present in both until about age two years. Chronic constipation has required medical intervention in both. They do not have involuntary movements or stereotypic hand movements and sleep well. They have been treated conservatively for esotropia and the younger girl uses glasses. Vision and hearing appear otherwise normal. On exam, they are short thin girls with dark circles infraorbitally, eyelid ptosis, alternating esotropia, hypotonic facies (Figures 1 C, D) and small hands and feet.
Subject F3-II.1, who was more hypotonic at birth than her sister, was an undemanding baby who slept a lot. She now pulls to a stand from sitting, walks with a walker for up to an hour at a time and uses her hands to bring food to her mouth. Epilepsy was diagnosed at age three years, but in retrospect she most likely had atonic seizures from age six months. Her seizure disorder has been difficult to manage from around age 10 years and a vagal nerve stimulator was implanted at age 12 years. She has only recently had a G-tube placed in order to deliver anti-convulsants more reliably and to supplement oral caloric intake when needed. Her daytime sleepiness seems related to seizure activity and side effects of medications. She has developed a mild scoliosis.
Subject F3-II.3 has been completely G-tube fed since age 11 months. She reacts to nutritional supplements with malaise and vomiting, and therefore receives the majority of her caloric intake as liquefied regular food. She has gastro-oesophageal reflux that responds to medical treatment. She can manoeuvre from the prone to sitting without assistance and sits stably while using both arms to manipulate toys.
The sisters have experienced multiple seizure types (Table 1) , but both display a strikingly similar EEG pattern characterized by encephalopathic background activity with frequent spike and wave discharges ( Figure S1 ).
Cranial MRI was normal in both as were the following investigations: expanded 
